Xencor, Inc., incorporated on June 8, 2004, is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. The Company uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. The Company is developing a suite of clinical candidates using two of its Fc technology platforms. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
XmAb5871
The Company's XmAb5871 uses its XmAb Immune Inhibitor Fc domain and targets B cells, a component of the immune system. It is conducting a Phase II open-label pilot study of XmAb5871 for IgG4-RD. The trial design is for patients to receive every other week IV administration of XmAb5871 for up to 24 weeks and the primary objective of the study is to evaluate the effect of XmAb5871 on disease activity using the reported IgG4-RD Responder Index in patients with active IgG4-RD. it is enrolling a Phase II randomized, double blinded, placebo-controlled study of XmAb5871in Systemic Lupus Erythematosus (SLE). This trial is designed to assess the effect of XmAb5871 on SLE disease activity in a shorter timeframe.
XmAb7195
The Company's XmAb7195 uses its Immune Inhibitor Fc Domain. XmAb7195 is designed to reduce blood serum levels of IgE, which mediates allergic responses and allergic disease. It initiated a Phase I trial for XmAb7195 with a subcutaneous formulation. The first part of the trial is an open-label, parallel group, multi-dose study to establish a safety dose for subcutaneous XmAb7195 in healthy volunteers. The second part of the trial is a randomized, double-blind, placebo-controlled, multiple ascending dose study in healthy volunteers and atopic subjects with XmAb7195.
XmAb14045
The Company's XmAb14045 uses its XmAb bispecific Fc technology that allows it to create dual-antigen targeting molecules. XmAb14045 targets CD123, an antigen on AML cells and leukemic stem cells, and CD3, an activating receptor on T cells. The trial is a Phase I, open-label, multiple-dose, dose escalation study to assess safety, tolerability and preliminary anti-tumor activity in AML.
XmAb13676
The Company's XmAb13676 is a bispecific oncology candidate. XmAb13676 targets CD20, an antigen on B-cell tumors, and CD3 for the treatment of B-cell malignancies, and is a tumor-targeted antibody that contains both a tumor antigen binding domain (CD20) and a cytotoxic T-cell binding domain (CD3). The trial will be a Phase I, open-label, multiple-dose, dose escalation study to assess tolerability and preliminary anti-tumor activity in B-cell malignancies.
The Company competes with GlaxoSmithKline, Roche/Genentech, Novartis AG, AstraZeneca plc and Regeneron Pharmaceuticals.
111 W Lemon Ave
The company trades on NASDAQ exchange. The company headquarter is located in California, CA. The company was established in the 1997.| Ticker | XNCR |
| Long Name | Xencor, Inc. |
| Short Name | Xencor |